Skip to content

Study · Non-randomized trial · n = 35 · 2022

6 results

The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes.

Zhang L, Hu Y, An Y, Wang Q, Liu J, Wang G

Frontiers in endocrinology31 Mar 2022Cited by 21 (Europe PMC)

PMID35432194 (opens in a new tab)PMCIDPMC9009038 (opens in a new tab)DOI10.3389/fendo.2022.677202 (opens in a new tab)PepBankPUB-35432194
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

ObjectiveExenatide has been demonstrated beneficial effects on patients with type 2 diabetes mellitus (T2DM) regarding lipid metabolism. However, the potential mechanism remains unclear. We used a lipidomic approach to evaluate lipid changes in response to treatment with exenatide in T2DM patients.MethodsSerum lipidomic profiles of 35 newly diagnosed T2DM patients (before and after exenatide treatment) and 20 age-matched healthy controls were analyzed by ultrahigh-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.ResultsA total of 45 lipid species including sphingomyelins (SMs), ceramides (CERs), lysophosphatidylcholines (LPCs), phosphatidylethanolamines (PEs), lysophosphatidylethanolamines (LPEs) and phosphatidylcholines (PCs) were identified in all participants. Compared to the healthy controls, 13 lipid species [SM (d18:1/18:0, d18:1/18:1), Cer (d18:1/18:0, d18:1/16:0, d18:1/20:0, d18:1/24:1), LPC (15:0, 16:0, 17:0), PC (19:0/19:0), LPE (18:0) and PE (16:0/22:6, 18:0/22:6)] were markedly increased in the T2DM group, while PE (17:0/17:0) and PC (18:1/18:0) were decreased (P < 0.05). The serum SM (d18:1/18:0, d18:1/18:1), LPC (16:0), and LPE (18:0) were significantly decreased after exenatide treatment, which was accompanied by the amelioration of lipids and glycemic parameters (TC, LDL-C, ApoA-I, FCP and HbA1c) in T2DM patients. The chord diagrams showed distinct correlation patterns between lipid classes and subclasses among healthy controls, T2DM patients before and after exenatide treatment.ConclusionOur results revealed that the therapeutic benefits of exenatide on T2DM might be involved in the improved lipid metabolism, especially SM, LPC, and LPE.Clinical trial registrationClinicalTrials.gov, identifier NCT03297879.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with diabetes, serum SM d18:1/18:0 decreased after exenatide treatment.

    In plain wordsIn patients with diabetes, serum SM d18:1/18:0 decreased after exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSM d18:1/18:0
    Study

    n = 35

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The serum SM (d18:1/18:0, d18:1/18:1), LPC (16:0), and LPE (18:0) were significantly decreased after exenatide treatment,
    1 context sentence
    Summary · context
    Serum lipidomic profiles of 35 newly diagnosed T2DM patients (before and after exenatide treatment) and 20 age-matched healthy controls were analyzed by ultrahigh-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with diabetes, serum SM d18:1/18:1 decreased after exenatide treatment.

    In plain wordsIn patients with diabetes, serum SM d18:1/18:1 decreased after exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSM d18:1/18:1
    Study

    n = 35

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The serum SM (d18:1/18:0, d18:1/18:1), LPC (16:0), and LPE (18:0) were significantly decreased after exenatide treatment,
    1 context sentence
    Summary · context
    Serum lipidomic profiles of 35 newly diagnosed T2DM patients (before and after exenatide treatment) and 20 age-matched healthy controls were analyzed by ultrahigh-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with diabetes, serum LPC 16:0 decreased after exenatide treatment.

    In plain wordsIn patients with diabetes, serum LPC 16:0 decreased after exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLPC 16:0
    Study

    n = 35

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The serum SM (d18:1/18:0, d18:1/18:1), LPC (16:0), and LPE (18:0) were significantly decreased after exenatide treatment,
    1 context sentence
    Summary · context
    Serum lipidomic profiles of 35 newly diagnosed T2DM patients (before and after exenatide treatment) and 20 age-matched healthy controls were analyzed by ultrahigh-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with diabetes, serum LPE 18:0 decreased after exenatide treatment.

    In plain wordsIn patients with diabetes, serum LPE 18:0 decreased after exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLPE 18:0
    Study

    n = 35

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The serum SM (d18:1/18:0, d18:1/18:1), LPC (16:0), and LPE (18:0) were significantly decreased after exenatide treatment,
    1 context sentence
    Summary · context
    Serum lipidomic profiles of 35 newly diagnosed T2DM patients (before and after exenatide treatment) and 20 age-matched healthy controls were analyzed by ultrahigh-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with diabetes, exenatide treatment accompanied reported improvement in TC, LDL-C, ApoA-I, FCP and HbA1c without individual directions.

    In plain wordsIn patients with diabetes, exenatide treatment accompanied reported improvement in lipid and glycemic parameters without individual directions.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedRoutine lipid and glycemic parameters
    Study

    n = 35

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The serum SM (d18:1/18:0, d18:1/18:1), LPC (16:0), and LPE (18:0) were significantly decreased after exenatide treatment, which was accompanied by the amelioration of lipids and glycemic parameters (TC, LDL-C, ApoA-I, FCP and HbA1c) in T2DM patients.
    1 context sentence
    Summary · context
    Serum lipidomic profiles of 35 newly diagnosed T2DM patients (before and after exenatide treatment) and 20 age-matched healthy controls were analyzed by ultrahigh-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 06HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialOther

    In serum lipidomic analyses, lipid correlation patterns differed among healthy controls and patients with diabetes before and after exenatide.

    In plain wordsIn serum lipidomic analyses, lipid correlation patterns differed among healthy controls and patients with diabetes before and after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedLipid correlation patterns
    Study

    n = 55

    Comparator
    Healthy controls and pretreatment diabetes samples
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    The chord diagrams showed distinct correlation patterns between lipid classes and subclasses among healthy controls, T2DM patients before and after exenatide treatment.
    1 context sentence
    Summary · context
    Serum lipidomic profiles of 35 newly diagnosed T2DM patients (before and after exenatide treatment) and 20 age-matched healthy controls were analyzed by ultrahigh-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03297879

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

Beijing Chao Yang Hospitaln = 2301 Jan 2013 to 28 Feb 2016

Type2 Diabetes

Trial pageClinicalTrials.govUpdated 2 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.